香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不會就本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Fangzhou Inc. 方舟云康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6086） 根據上市規則第13.10條作出之公告 經作出在相關情況下有關本公司的該等合理查詢後，董事會確認(i)新聞稿所 含資料並不構成根據上市規則第13.09(2)條或香港法例第571章證券及期貨條 例第XIVA部項下之內幕消息條文所規定之內幕消息；及(ii)其亦並不知悉股 份交易價格上升之任何理由，或為避免股份出現虛假市場而須作出公告之任 何資料，或須予披露之任何內幕消息。 本公司股東及潛在投資者於買賣股份時務請審慎行事。 本公告乃根據本公司之命令而作出。董事會就本公告之準確性全體及個別承 擔責任。 承董事會命 方舟云康控股有限公司 主席 謝方敏先生 香港，2025年9月14日 本公告乃應香港聯合交易所有限公司（「聯交所」）要求根據聯交所證券上市 規則（「上市規則」）第13.10條作出。方舟云康控股有限公 ...

Core Insights - The article emphasizes that chronic disease management in China is entering a new era driven by AI, highlighting the importance of technology in addressing healthcare challenges posed by an aging population [1][2] - The online chronic disease management market in China is projected to grow significantly, with a compound annual growth rate of 44.5%, from 45.5 billion yuan in 2023 to 600 billion yuan by 2030 [1] - Ark Health's AI-driven approach aims to create a patient-centered healthcare model, leveraging technology to enhance doctor-patient relationships and improve service efficiency [2][3] Technology Development - Ark Health's "Xing Shi Medical Model" is designed to integrate various intelligent components into a collaborative service team, aiming for state-of-the-art performance [3] - The AI assistant has reportedly saved doctors over 60,000 hours of time through its diagnostic and case analysis capabilities [3] - The company has developed five core AI products, including AI Medication Finder and AI Health Manager, which aim to enhance clinical decision-making and knowledge dissemination [4] Strategic Collaborations - Ark Health has formed strategic partnerships with pharmaceutical companies, such as Innovent Biologics, to target the rapidly growing weight management market, which is expected to reach 149 billion yuan by 2030 [6][7] - The collaboration with Innovent focuses on integrating AI technology with innovative weight loss products, providing comprehensive support for patients [6][8] - The partnership with Zhejiang Otsuka Pharmaceutical aims to enhance drug service offerings and health education through AI capabilities [7][8]

Major Events - China Power (02380) plans to acquire a 31% stake in Dazhou Energy [1] - Shun Teng International Holdings (00932) received a 20% discount from Chairman Zhang Shaohui for a full acquisition offer [1] - Huajian Medical (01931) established a joint venture to deepen the global blockchain financial ecosystem strategy through the "ETHK" core brand [1] - Derin Holdings (01709) signed a strategic cooperation and investment agreement with Winner Fashion (03709) [1] - Dongwu Cement (00695) major shareholder Goldview intends to sell a total of 204 million shares, making Hong Kong Aviation the single largest shareholder [1] - CSPC Pharmaceutical Group (01093) received clinical trial approval for SYH2066 tablets in China [1] - GAC Group (02238) plans to issue up to 15 billion yuan in corporate bonds and 15 billion yuan in medium-term notes [1] - Huatai Securities (06886) plans to issue up to 6 billion yuan in corporate bonds [1] - Ark Health (06086) stated that the H2H conference news is not insider information and is unaware of the reason for the stock price increase [1] Financial Data - China Resources Land (01109) reported a cumulative contract sales amount of 136.8 billion yuan for the first eight months, a year-on-year decrease of 12.0% [1] - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 73.011 billion yuan for the first eight months, a year-on-year increase of approximately 3.7% [1] - Zhong An Online (06060) reported a total original insurance premium income of approximately 23.625 billion yuan for the first eight months, a year-on-year increase of 6.36% [1]

Core Insights - Fangzhou Inc. has launched its proprietary "XingShi" Large Language Model (XS LLM) aimed at improving chronic disease management through enhanced service efficiency and personalization [1][4] - The XS LLM integrates multimodal capabilities including image and speech recognition, natural language processing, and large-scale medical knowledge storage, supporting five domain-specific intelligent agents [2] - The model serves as the core digital brain of Fangzhou's platform, powering five AI-enabled applications that facilitate real-time interventions in medication guidance, patient education, and diagnostic assistance [3] Company Overview - Fangzhou Inc. is a leading online chronic disease management platform in China, with 52.8 million registered users and 229,000 physicians as of June 30, 2025 [5] - The company specializes in tailored medical care and AI-enabled precision medicine solutions, reflecting its commitment to scalable and accessible healthcare delivery [4][5]

Core Insights - The board of Ark Health (06086.HK) noted a recent increase in the company's share price on September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model as a cornerstone for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - Strategic partnerships were established with Innovent Biologics and Otsuka Pharmaceutical to integrate digital health solutions and improve patient outcomes in the growing weight management market in China [1] Summary by Categories - **Share Price Movement** - The board observed a rise in the company's share price on September 12, 2025 [1] - **Product Development** - The company launched the "Xing Shi" large model, which serves as the foundation for five key applications: AI Drug Assistant, AI Health Manager, AI Doctor Assistant, AI Academic Assistant, and AI Search [1] - **Strategic Partnerships** - A partnership with Innovent Biologics was formed to integrate Ark's digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital support [1] - Collaboration with Otsuka Pharmaceutical aims to combine AI technology with Otsuka's innovative drug portfolio to develop comprehensive digital solutions for drug support services and health education programs [1]

Core Viewpoint - Ark Health (06086) has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025, following the announcement of its strategic initiatives and partnerships in the healthcare sector [1]. Group 1: Company Developments - The company has launched its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications, including AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, aimed at enhancing clinical diagnostic support and personalized chronic disease management [1]. - Ark Health has formed a strategic partnership with Innovent Biologics to integrate its H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model to provide personalized digital maintenance and adherence support for Innovent's Ma Shidu peptide in China's rapidly growing weight management market [1]. - The company has also entered into a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., combining its AI technology advantages with Otsuka's innovative drug portfolio to jointly develop comprehensive digital solutions covering drug support services, targeted patient outreach programs, and health education initiatives [1]. Group 2: Regulatory Confirmation - The board has confirmed that the information contained in the press release does not constitute inside information as defined under the Listing Rules and relevant securities regulations, and it is unaware of any reasons for the increase in share price or any information that needs to be disclosed to avoid creating a false market in its shares [2].

Group 1 - The company, Ark Health (06086), has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - A strategic partnership has been established with Innovent Biologics to integrate Ark's H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital maintenance and compliance support in China's growing weight management market [1] - The company has also formed a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., Ltd. to develop comprehensive digital solutions that combine AI technology with Otsuka's innovative drug portfolio, focusing on drug support services, targeted patient outreach programs, and health education initiatives [1] Group 2 - The board confirmed that the information contained in the press release does not constitute insider information as defined under the relevant listing rules and securities regulations [2] - The board is not aware of any reasons for the increase in share price or any information that would require disclosure to prevent a false market in the shares [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不會就本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本公司股東及潛在投資者於買賣股份時務請審慎行事。 本公告乃根據本公司之命令而作出。董事會就本公告之準確性全體及個別承 擔責任。 承董事會命 Fangzhou Inc. 方舟云康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6086） 根據上市規則第13.10條作出之公告 本公告乃應香港聯合交易所有限公司（「聯交所」）要求根據聯交所證券上市 規則（「上市規則」）第13.10條作出。方舟云康控股有限公司（「本公司」）董 事會（「董事會」）留意到，本公司股份（「股份」）近期於2025年9月12日在聯 交所的價格有所上升。 董事會亦留意到，本公司就其於2025年9月10日舉行的第十屆H2H醫療服務 生態大會而刊發的新聞稿（「新聞稿」），其中包括若干本公司之最新消息， 包括(i)本公司發佈專有「杏石」大模型（「杏石大模型」）作為其五項旗艦應用 （AI用藥助手、AI健康管家、AI醫生助手、AI學術助手 ...

Core Insights - Fangzhou Jianke has achieved profitability with a revenue of 1.494 billion yuan, marking a 12.9% growth, and a net profit of 12.5 million yuan as of mid-2025 [3] - The company employs a "familiar doctor-patient" model, focusing on relationship reconstruction rather than merely chasing traffic [4][5] - The AI-powered "Xing Shi Medical Model" aims to enhance the efficiency of its H2H (Hospital to Home) healthcare ecosystem [6][9] Company Performance - Fangzhou Jianke's user base has grown to over 52.8 million registered users and 229,000 registered doctors by mid-2025, with a high repurchase rate of 84.7% among paying users [4] - The company’s growth is driven by value-based internal growth, reducing reliance on continuous traffic purchases [5] AI Integration - The "Xing Shi Medical Model" integrates a comprehensive knowledge base from the Chinese Medical Association, covering over 1.1 million articles across 170 core journals [6] - Five core AI products have been launched, creating a collaborative network across medical, patient, and enterprise sectors [7] Efficiency Improvements - The AI Doctor Assistant has saved over 60,000 hours of work for doctors by providing nearly 400,000 technical assists, allowing them to focus on more complex diagnoses [8] - The AI Health Manager has reduced average consultation times by over 70%, significantly enhancing patient experience [8] Future Vision - By 2025, the company aims to integrate AI assistants into daily medical practices, with daily usage exceeding 100,000 times [10] - The ultimate goal is to establish "Fangzhou Medical Smart Cloud" by 2027, serving as an authoritative clinical decision standard across the industry [10]

Core Viewpoint - Ark Health (06086) has seen a significant stock price increase following the announcement of a strategic partnership with Innovent Biologics to enhance AI-driven chronic disease management solutions [1] Group 1: Stock Performance - Ark Health's stock rose over 7% during trading, with a current increase of 6.65%, reaching HKD 4.65, and a trading volume of HKD 28.54 million [1] Group 2: Strategic Partnership - On September 10, Ark Health signed a strategic cooperation agreement with Innovent Biologics at the 10th H2H Medical Service Ecosystem Conference [1] - The partnership aims to leverage Ark Health's AI technology and industry experience to transform the management process for chronic disease patients, creating a personalized and integrated health management experience [1] Group 3: AI-Driven Services - The collaboration will focus on integrating innovative treatment solutions with AI-driven health management, particularly in the "AI + Weight Loss" service sector [1] - In the pharmaceutical service area, the AI medication assistant will provide 24/7 online consultation, medication inquiries, and support for obesity patients, breaking traditional service limitations [1] - The AI health manager will serve as a constant health management partner, offering personalized medication guidance, service reminders, report interpretation, and educational resources, enhancing patient health literacy and self-management capabilities [1]